Is Wegovy good for heart patients — and what does the evidence actually say?

You've been told to lose weight for your heart, here's why your GP may now mention Wegovy

Picture a familiar scenario: you've had a heart attack, or you're managing angina, and your cardiologist's notes keep returning to your weight. Diets have come and gone. You're not looking for a quick fix; you want to know whether a medicine with a genuine evidence base exists. That's an entirely reasonable question, and the answer is more substantial than you might expect.

In 2023, researchers published results from the SELECT trial, a study following more than 17,000 adults aged 45 and over who had established cardiovascular disease (a previous heart attack, stroke or peripheral arterial disease) and a BMI of 27 or above, but who did not have type 2 diabetes. Participants received either weekly semaglutide 2.4mg or a placebo, alongside standard care. After an average follow-up of just over three years, the semaglutide group showed a roughly 20% relative reduction in the composite risk of cardiovascular death, non-fatal heart attack and non-fatal stroke. The SELECT trial findings, published in the New England Journal of Medicine, led directly to the MHRA granting Wegovy a second UK authorisation specifically covering cardiovascular risk reduction, a separate licence from the weight-management indication.

One detail from SELECT that clinicians find particularly striking: the benefit appeared across participants regardless of how much weight they lost. That hints at anti-inflammatory or other direct vascular effects of semaglutide, though the full mechanism is still being studied. If you want to understand what the evidence actually shows, our page on whether Wegovy is good for the heart goes into the trial data and proposed mechanisms in detail. For patients, the practical upshot is that this is not simply a weight-loss drug being repurposed; it is a medicine with its own cardiovascular evidence base.

Which heart patients the cardiovascular licence actually covers, and which situations still need careful thought

The UK cardiovascular authorisation for Wegovy is specific. It applies to adults with a BMI of 27 or above who have established cardiovascular disease (meaning a prior heart attack, prior stroke, or symptomatic peripheral arterial disease) and who are using the medicine alongside standard care (statins, antihypertensives and so on, as clinically appropriate). It is not a blanket green light for anyone with a heart condition; newly diagnosed arrhythmias, uncontrolled heart failure or recent cardiac surgery each represent situations where a prescriber needs to assess individual risk carefully.

There are also interactions worth understanding. If you take medicines whose absorption could be affected by slowed gastric emptying (a known effect of GLP-1 receptor agonists) your prescriber will want to review your medication list. Oral anticoagulants (warfarin) and oral contraceptives are the most commonly discussed examples, though for semaglutide the evidence on oral contraceptive absorption is less prominent than it is for tirzepatide. You can read more about the evidence behind semaglutide and cardiovascular health if you want a deeper look at the mechanisms.

Side effects in the cardiac population are broadly the same GI-led profile seen in the weight-management trials: nausea, loose stools and reduced appetite are most common, particularly in the early weeks. These can be significant if you are also managing heart failure or have a restricted fluid intake, which is another reason a prescriber who knows your situation matters here. The NHS patient information page for semaglutide sets out what to watch for and when to seek urgent help.

What about other conditions that often travel alongside heart disease?

Heart disease rarely arrives alone. Many people asking about Wegovy and heart health are also managing type 2 diabetes, chronic kidney disease, or fatty liver disease, and semaglutide has an expanding evidence base across all three. The MHRA approved Wegovy for a form of metabolic liver disease (MASH) in July 2026. Kidney outcomes data also exist, though the renal indication is not yet part of Wegovy's UK licence for weight management or cardiovascular purposes. If kidney health is part of your picture, our page on Wegovy and kidney health covers what the research currently shows.

For those whose heart disease sits alongside type 2 diabetes, the landscape overlaps with the older semaglutide cardiovascular outcome trials (SUSTAIN-6 and SOUL, in the diabetes context) as well as newer data. How semaglutide performs in type 2 diabetes is a distinct question with its own evidence, and one our prescribers can discuss in the context of your overall treatment plan.

If you are thinking about what treatment might be right for you and want to understand the full picture (weight management, cardiac history, current medicines) exploring the weight-loss treatment options available through nume is a sensible starting point before booking a consultation.

Getting Wegovy through a regulated route if you have heart disease

If your cardiologist or GP has suggested looking into Wegovy, or if you have read the SELECT data yourself and want to discuss it with a prescriber, the practical question becomes: how do you access it safely?

Wegovy is available on the NHS through specialist weight management services, though waiting lists for those services can be considerable. Privately, it is available through regulated online pharmacies, but the standard of clinical review varies significantly between providers. For anyone with an existing cardiac condition, a superficial online questionnaire is not enough. You need a prescriber who will read your cardiac history, check your current medication list, and consider whether Wegovy's interactions or side-effect profile create any specific concerns for you.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day, a real clinician, not automated decision-making. You can verify our pharmacy on the GPhC register (registration 9012878) at pharmacyregulation.org. We are not the cheapest option available. What that buys you is a prescriber who takes your cardiac background seriously before any treatment is agreed. It is also worth knowing that Wegovy and pregnancy require particular consideration, so if that is relevant to your circumstances our prescribers will factor it into your assessment. For more detail on how Wegovy works in the context of heart health, our dedicated cardiovascular page goes further on the mechanisms and trial data.

If this sounds like the kind of clinical conversation you've been looking for, speak to our prescribers through a free consultation, and bring your questions about your heart history. That's exactly what the consultation is for.